Sequana Medical NV
Brussels Stock Exchange SEQUA.BR
Sequana Medical NV Price to Sales Ratio (P/S) on January 14, 2025: 177.62
-
Sequana Medical NV 52-week high Price to Sales Ratio (P/S) is 258.63 on December 30, 2024, which is 45.61% above the current Price to Sales Ratio (P/S).
-
Sequana Medical NV 52-week low Price to Sales Ratio (P/S) is 40.87 on December 19, 2024, which is -76.99% below the current Price to Sales Ratio (P/S).
-
Sequana Medical NV average Price to Sales Ratio (P/S) for the last 52 weeks is 157.39.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Ian Crosbie |
| IPO Date | Feb. 11, 2019 |
| Location | Belgium |
| Headquarters | Kortrijksesteenweg 1112 |
| Employees | 62 |
| Sector | Health Care |
| Industries | |
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Past 5 years
USD 673.61
StockViz Staff
January 15, 2025
Any question? Send us an email